Equillium (EQ)
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in...
- Open
- 2.210
- High
- 2.240
- Low
- 2.152
- Prev. Close
- 2.200
- Volume
- 606.01K
- Turnover
- 1.32M
- Avg Price
- 2.186
- Bid/Ask Ratio
- --
- Amplitude
- 4.00%
- 52wk High
- 3.540
- Volume Ratio
- 1.50
- Turnover Ratio
- 1.64%
Equillium Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$8.56292.46%
Forecast & RatingStrong buy
9analysts
- Strong buy88.89%
- Buy11.11%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 20 at 04:00 PM
EQ Inc. Q2 FY26 net loss widens to C$466,000; revenue rises 40% vs Q1 to C$2.64 million
- benzinga_article · Aug 14 at 01:40 PM
Equillium shares are trading higher after the company reported better-than-expected Q2 EPS results.
- Market Beat · Aug 13 at 07:41 PM
Equillium (NASDAQ:EQ) Announces Earnings Results
- Quartr · Aug 13 at 06:14 PM
EQ: EQ504 targets UC with a novel, validated approach, backed by strong science and financial runway
- Unusual Whales · Aug 13 at 03:07 PM
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- PUBT · Aug 13 at 06:06 AM
MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million
